The products offered on this website (except supplements) are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
All articles and product information provided on this website is for informational and educational purposes only.
IDRA-21 has been introduced to the market fairly recently. It acts as an ampakine stimulant drug and studies are currently being undertaken to further research its effects into memory improvement, cognitive enhancement, stimulation, and reversing cognitive deficits.
Ampakine stimulants are allosteric modulators of AMPA receptors in the brain. These AMPA receptors are in charge of fast synaptic transmission and are involved in synaptic plasticity and long term potentiation.
Being an ampakine the IDRA-21 works through the modulation of AMPA receptors in the brain. It is responsible for binding the allosteric site and subsequently forcing positive modulation. Some refer to this process as allosteric activation.
To date, studies have focused almost exclusively on determining its potential for the treatment of a series of conditions of neurological nature such as Alzheimer's disease, Parkinson's disease, and the cognitive deterioration that stems from the aging process.
Animal-based tests have proven that IDRA-21 gives users cognitive enhancement that is long-lasting. This manifests itself in improved memory and learning skills after just one dose.
It is worth noting however that those who tried IDRA-21 experienced side effects that are commonly associated with the use of nootropics and ampakines. These side effects include: headaches, mood swings, dizziness, anxiety, insomnia, nausea, sweating, and restlessness.